Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Asthma 

Once-daily ICS-LABA-LAMA superior to ICS-LABA in improving lung function, research suggests

A study in The Lancet Respiratory Medicine indicates that a single-inhaler combination of inhaled corticosteroid, long-acting β2-adrenoceptor agonist, and long-acting muscarinic receptor antagonist works well to improve lung function in patients with asthma.

Asthma inhaler

Source: Shutterstock.com

The researchers said that a once-daily dosage regimen and administration via a single inhaler might improve treatment adherence and, ultimately, asthma control in a real-world setting

A once-daily, single-inhaler combination of inhaled corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and long-acting muscarinic receptor antagonist (LAMA) was superior to ICS–LABA in improving lung function in patients with inadequately controlled asthma, a study funded by Novartis has suggested[1].

The researchers included 3,092 patients aged 18–75 years with symptomatic asthma despite treatment with medium-dose or high-dose ICS–LABA, at least one exacerbation in the previous year, and a percentage of predicted FEV1 of less than 80%.

Participants were randomised to receive one year of medium or high-dose mometasone–indacaterol–glycopyrronium (MF–IND–GLY) or mometasone–indacaterol (MF–IND) once daily, or twice daily fluticasone–salmeterol (FLU–SAL), a well-established ICS–LABA combination.

At week 26, the researchers found that medium and high-dose MF–IND–GLY showed superior improvement in trough FEV1, the mean volume of air that can be forced out in one second after taking a deep breath immediately before the next dose of study drug, compared with the corresponding doses of MF–IND. Medium and high-dose MF–IND–GLY also led to a greater improvement in trough FEV1 compared with high-dose FLU–SAL. Incidence of adverse events was balanced across the treatment groups.

In The Lancet Respiratory Medicine, the researchers said that the combination of ICS–LABA–LAMA containing a medium dose of ICS had the potential to offer similar or better disease control than ICS–LABA combinations containing high ICS doses.

“A once-daily dosage regimen and administration via a single inhaler might improve treatment adherence and, ultimately, asthma control in a real-world setting,” they added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208267

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.